Abstract 4706: Evaluating the efficacy of RAS(ON) inhibitor RMC-6236 combined with chemotherapy and other targeted therapies in 3D models involving patients with KRAS-mutated pancreatic cancer
Taylor Bargenquast(HonorHealth), Sunil Sharma(HonorHealth), Mohan R. Kaadige(University of Utah), Janith Don(Translational Genomics Research Institute), Guangfa Zhang(Zhejiang University), Tithi Ghosh(Translational Genomics Research Institute), Trason Thode(Translational Genomics Research Institute), C. John Wesley(Translational Genomics Research Institute), Serina Ng(Translational Genomics Research Institute), Raffaella Soldi(Translational Genomics Research Institute), Erkut Borazanci(HonorHealth), Alexis Weston(Translational Genomics Research Institute), Nicholas J. Schork(Translational Genomics Research Institute), Sara A. Byron(Translational Genomics Research Institute)
Cited by 1
Related Papers
Genetic Dissection of Complex Traits
|Science|1994|3.5k
Whole-genome sequencing identifies common-to-rare variants associated with human blood metabolites
|Nature Genetics|2017|485
Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer
|JAMA Oncology|2019|289
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)
|Clinical Cancer Research|2019|260
Silicone Oil-Infused Slippery Surfaces Based on Sol–Gel Process-Induced Nanocomposite Coatings: A Facile Approach to Highly Stable Bioinspired Surface for Biofouling Resistance
|ACS Applied Materials & Interfaces|2016|182